home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.04 -2.64 (-13.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Why Summit Therapeutics Stock Rocketed 6% Higher on Friday ↗

December 06, 2024

Via The Motley Fool

Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher ↗

December 02, 2024

Via The Motley Fool

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

November 30, 2024

Via The Motley Fool

Summit Therapeutics to Present at Upcoming Investor Conferences

November 26, 2024

From Summit Therapeutics Inc.

Via Business Wire

3 Monster Stocks in the Making ↗

November 23, 2024

Via The Motley Fool

Preview: Summit Therapeutics's Earnings ↗

October 29, 2024

Via Benzinga

(SMMT) - Analyzing Summit Therapeutics's Short Interest ↗

October 10, 2024

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2024

From Summit Therapeutics Inc.

Via Business Wire

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗

November 14, 2024

Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.

Via Investor's Business Daily

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗

November 09, 2024

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus.

Via Benzinga

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

2 Hot Biopharma Stocks to Buy and Hold for 5 Years ↗

November 08, 2024

If you're patient, these businesses have a lot of promising projects in the works.

Via The Motley Fool

Why Summit Therapeutics Stock Was a Winner Today ↗

November 04, 2024

A cancer drug has vast potential for the company, says a pundit newly following it.

Via The Motley Fool

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗

November 04, 2024

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results.

Via Benzinga

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?

November 04, 2024

Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway.

Via MarketBeat

This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 04, 2024

Via Benzinga

3 Magnificent Stocks Under $100 to Buy in November ↗

November 03, 2024

The price could be right for these stocks.

Via The Motley Fool

2 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

November 02, 2024

These are the kinds of stocks that can allow investors to sleep easy at night.

Via The Motley Fool

3 Stocks That Have Generated 1,000% Returns in Just 2 Years ↗

October 31, 2024

Should you add these fast-growing stocks to your portfolio?

Via The Motley Fool

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

October 30, 2024

From Summit Therapeutics Inc.

Via Business Wire

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

October 28, 2024

The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).

Via News Direct

Is Summit Therapeutics a Millionaire Maker? ↗

October 27, 2024

The potential upside of this stock is undeniably meaty.

Via The Motley Fool

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗

October 24, 2024

This drugmaker's lead candidate could become a top-selling cancer therapy.

Via The Motley Fool

Billionaire Bob Duggan Snags $33M Miami Penthouse Amid Summit Therapeutics 689% Stock Rally ↗

October 24, 2024

Duggan, an 80-year-old originally from California, was particularly impressed by the breathtaking views from the 57th floor.

Via Benzinga

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

October 23, 2024

From Summit Therapeutics Inc.

Via Business Wire

Billionaire Israel Englander Just Quietly Took a Stake in This Potentially Lucrative Pharmaceutical Stock. Should You? ↗

October 22, 2024

Millennium Management just initiated a position in a small biotech company developing a new cancer drug.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Up 700% This Year, Is It Too Late to Invest in This Stock? ↗

October 15, 2024

The shares have experienced a pullback in the past couple of weeks.

Via The Motley Fool

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics ↗

October 13, 2024

It's hard to go wrong with either company, but one is more appealing.

Via The Motley Fool

3 Things You Need to Know If You Buy Summit Therapeutics Stock Today ↗

October 12, 2024

It's easier to invest confidently when you know both the pros and the cons in full.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com